Logo image of PHH

PARK HA BIOLOGICAL TECHNOLOG (PHH) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:PHH - KYG6925R1020 - Common Stock

0.385 USD
0 (-0.08%)
Last: 10/27/2025, 8:00:00 PM
0.4112 USD
+0.03 (+6.81%)
After Hours: 10/27/2025, 8:00:00 PM
Fundamental Rating

3

PHH gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 122 industry peers in the Specialty Retail industry. PHH has a great financial health rating, but its profitability evaluates not so good. PHH is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

PHH had negative earnings in the past year.
PHH had a positive operating cash flow in the past year.
PHH Yearly Net Income VS EBIT VS OCF VS FCFPHH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 500K 1M

1.2 Ratios

PHH's Return On Assets of -331.89% is on the low side compared to the rest of the industry. PHH is outperformed by 97.54% of its industry peers.
PHH has a worse Return On Equity (-455.43%) than 79.51% of its industry peers.
Industry RankSector Rank
ROA -331.89%
ROE -455.43%
ROIC N/A
ROA(3y)20.25%
ROA(5y)N/A
ROE(3y)81.07%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PHH Yearly ROA, ROE, ROICPHH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 20 40 60 80 100

1.3 Margins

The Gross Margin of PHH (92.99%) is better than 97.54% of its industry peers.
PHH does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 92.99%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PHH Yearly Profit, Operating, Gross MarginsPHH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 20 40 60 80

More info and screens

9

2. Health

2.1 Basic Checks

PHH does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PHH has less shares outstanding
PHH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PHH Yearly Shares OutstandingPHH Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 5M 10M 15M 20M 25M
PHH Yearly Total Debt VS Total AssetsPHH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 1M 2M 3M

2.2 Solvency

An Altman-Z score of 21.30 indicates that PHH is not in any danger for bankruptcy at the moment.
The Altman-Z score of PHH (21.30) is better than 100.00% of its industry peers.
There is no outstanding debt for PHH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 21.3
ROIC/WACCN/A
WACC8.04%
PHH Yearly LT Debt VS Equity VS FCFPHH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 500K 1M 1.5M

2.3 Liquidity

A Current Ratio of 3.68 indicates that PHH has no problem at all paying its short term obligations.
PHH has a better Current ratio (3.68) than 92.62% of its industry peers.
PHH has a Quick Ratio of 3.63. This indicates that PHH is financially healthy and has no problem in meeting its short term obligations.
PHH has a better Quick ratio (3.63) than 96.72% of its industry peers.
Industry RankSector Rank
Current Ratio 3.68
Quick Ratio 3.63
PHH Yearly Current Assets VS Current LiabilitesPHH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 500K 1M 1.5M 2M 2.5M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for PHH have decreased strongly by -2189.24% in the last year.
PHH shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 9.33%.
EPS 1Y (TTM)-2189.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-38931.58%
Revenue 1Y (TTM)9.33%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%45.29%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PHH Yearly Revenue VS EstimatesPHH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 500K 1M 1.5M 2M

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PHH. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PHH Price Earnings VS Forward Price EarningsPHH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Compared to the rest of the industry, the Price/Free Cash Flow ratio of PHH is on the same level as its industry peers.
Industry RankSector Rank
P/FCF 85.27
EV/EBITDA N/A
PHH Per share dataPHH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.02 -0.04 -0.06 -0.08

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

PHH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PARK HA BIOLOGICAL TECHNOLOG

NASDAQ:PHH (10/27/2025, 8:00:00 PM)

After market: 0.4112 +0.03 (+6.81%)

0.385

0 (-0.08%)

Chartmill FA Rating
GICS IndustryGroupConsumer Discretionary Distribution & Retail
GICS IndustrySpecialty Retail
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner Change0%
Market Cap13.04M
Revenue(TTM)3.62M
Net Income(TTM)-19.36M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 25.64
P/FCF 85.27
P/OCF 79.05
P/B 21.85
P/tB 21.88
EV/EBITDA N/A
EPS(TTM)-0.1
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0
FCFY1.17%
OCF(TTM)0
OCFY1.26%
SpS0.02
BVpS0.02
TBVpS0.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -331.89%
ROE -455.43%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 92.99%
FCFM 30.07%
ROA(3y)20.25%
ROA(5y)N/A
ROE(3y)81.07%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)99.2%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.62
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 318.59%
Cap/Sales 2.37%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.68
Quick Ratio 3.63
Altman-Z 21.3
F-Score5
WACC8.04%
ROIC/WACCN/A
Cap/Depr(3y)176.35%
Cap/Depr(5y)N/A
Cap/Sales(3y)1.71%
Cap/Sales(5y)N/A
Profit Quality(3y)314.24%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2189.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-38931.58%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)9.33%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%45.29%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-1586.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y742.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y659.29%
OCF growth 3YN/A
OCF growth 5YN/A

PARK HA BIOLOGICAL TECHNOLOG / PHH FAQ

Can you provide the ChartMill fundamental rating for PARK HA BIOLOGICAL TECHNOLOG?

ChartMill assigns a fundamental rating of 3 / 10 to PHH.


Can you provide the valuation status for PARK HA BIOLOGICAL TECHNOLOG?

ChartMill assigns a valuation rating of 1 / 10 to PARK HA BIOLOGICAL TECHNOLOG (PHH). This can be considered as Overvalued.


What is the profitability of PHH stock?

PARK HA BIOLOGICAL TECHNOLOG (PHH) has a profitability rating of 1 / 10.


What is the financial health of PARK HA BIOLOGICAL TECHNOLOG (PHH) stock?

The financial health rating of PARK HA BIOLOGICAL TECHNOLOG (PHH) is 9 / 10.